Successful Treatment With Bortezomib for Refractory and Complicated Acquired Thrombotic Thrombocytopenic Purpura in an Adolescent Girl

Basit Öğe Kaydı
dc.authoriduysal yazici, mutlu/0000-0001-7377-4718
dc.contributor.authorAzapagasi, Ebru
dc.contributor.authorYazici, Mutlu Uysal
dc.contributor.authorEroglu, Nilgun
dc.contributor.authorAlbayrak, Meryem
dc.contributor.authorKucur, Ozge
dc.contributor.authorFettah, Ali
dc.date.accessioned2025-01-21T16:44:37Z
dc.date.available2025-01-21T16:44:37Z
dc.date.issued2021
dc.departmentKırıkkale Üniversitesi
dc.description.abstractThrombotic thrombocytopenic purpura (TTP) is a rare, dangerous, life-threatening disease characterized by microangiopathic hemolytic anemia and thrombocytopenia, along with organ dysfunction due to microangiopathy-related ischemia. Plasma exchange and steroids are used for initial treatment, and rituximab is often used in refractive patients. Caplacizumab, cyclophosphamide, and splenectomy are among other treatment options. It has been reported that bortezomib, a proteasome inhibitor, can be used in the management of refractory acquired TTP. Herein, we present a 16-year-old female patient who was monitored for acquired TTP and treated with high-dose steroids, plasma exchange, rituximab, cyclophosphamide, and N-acetylcysteine but developed renal, cardiac, gastrointestinal, and neurologic complications. The girl was then successfully treated with bortezomib, and she has been monitored in remission for 6 months. We consider that bortezomib is a beneficial treatment, especially in patients with refractory TTP.
dc.identifier.doi10.1097/MPH.0000000000002026
dc.identifier.endpageE591
dc.identifier.issn1077-4114
dc.identifier.issn1536-3678
dc.identifier.issue4
dc.identifier.pmid33306607
dc.identifier.scopus2-s2.0-85098326897
dc.identifier.scopusqualityQ3
dc.identifier.startpageE587
dc.identifier.urihttps://doi.org/10.1097/MPH.0000000000002026
dc.identifier.urihttps://hdl.handle.net/20.500.12587/25496
dc.identifier.volume43
dc.identifier.wosWOS:000647760900041
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Pediatric Hematology Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241229
dc.subjectrefractory thrombotic thrombocytopenic purpura; bortezomib; children; rituximab; plasma exchange
dc.titleSuccessful Treatment With Bortezomib for Refractory and Complicated Acquired Thrombotic Thrombocytopenic Purpura in an Adolescent Girl
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu